Table of Contents

1 Study Coverage

• 1.1 Asthma & COPD Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Asthma & COPD Market Size Growth Rate by Product
  • 1.4.2 Anti-inflammatory Drugs
  • 1.4.3 Bronchodilator Monotherapy
  • 1.4.4 Combination Drugs
• 1.5 Market by End User
  • 1.5.1 Global Asthma & COPD Market Size Growth Rate by End User
  • 1.5.2 Hospital Pharmacies
  • 1.5.3 Private Clinics
  • 1.5.4 Drug Stores
  • 1.5.5 Retail Pharmacies
  • 1.5.6 E-Commerce
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Asthma & COPD Market Size
  • 2.1.1 Global Asthma & COPD Revenue 2014-2025
  • 2.1.2 Global Asthma & COPD Sales 2014-2025
• 2.2 Asthma & COPD Growth Rate by Regions
  • 2.2.1 Global Asthma & COPD Sales by Regions
  • 2.2.2 Global Asthma & COPD Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Asthma & COPD Sales by Manufacturers
  • 3.1.1 Asthma & COPD Sales by Manufacturers
  • 3.1.2 Asthma & COPD Sales Market Share by Manufacturers
  • 3.1.3 Global Asthma & COPD Market Concentration Ratio (CR5 and HHI)
• 3.2 Asthma & COPD Revenue by Manufacturers
  • 3.2.1 Asthma & COPD Revenue by Manufacturers (2014-2019)
  • 3.2.2 Asthma & COPD Revenue Share by Manufacturers (2014-2019)
• 3.3 Asthma & COPD Price by Manufacturers
• 3.4 Asthma & COPD Manufacturing Base Distribution, Product Types
  • 3.4.1 Asthma & COPD Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Asthma & COPD Product Type
  • 3.4.3 Date of International Manufacturers Enter into Asthma & COPD Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Asthma & COPD Sales by Product
• 4.2 Global Asthma & COPD Revenue by Product
• 4.3 Asthma & COPD Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Asthma & COPD Breakdown Data by End User

6 North America

• 6.1 North America Asthma & COPD by Countries
  • 6.1.1 North America Asthma & COPD Sales by Countries
  • 6.1.2 North America Asthma & COPD Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Asthma & COPD by Product
• 6.3 North America Asthma & COPD by End User

7 Europe

• 7.1 Europe Asthma & COPD by Countries
  • 7.1.1 Europe Asthma & COPD Sales by Countries
  • 7.1.2 Europe Asthma & COPD Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Asthma & COPD by Product
• 7.3 Europe Asthma & COPD by End User

8 Asia Pacific

• 8.1 Asia Pacific Asthma & COPD by Countries
  • 8.1.1 Asia Pacific Asthma & COPD Sales by Countries
  • 8.1.2 Asia Pacific Asthma & COPD Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Asthma & COPD by Product
• 8.3 Asia Pacific Asthma & COPD by End User

9 Central & South America

• 9.1 Central & South America Asthma & COPD by Countries
  • 9.1.1 Central & South America Asthma & COPD Sales by Countries
  • 9.1.2 Central & South America Asthma & COPD Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Asthma & COPD by Product
• 9.3 Central & South America Asthma & COPD by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Asthma & COPD by Countries
  • 10.1.1 Middle East and Africa Asthma & COPD Sales by Countries
  • 10.1.2 Middle East and Africa Asthma & COPD Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Asthma & COPD by Product
• 10.3 Middle East and Africa Asthma & COPD by End User

11 Company Profiles

• 11.1 GSK
  • 11.1.1 GSK Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 GSK Asthma & COPD Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 GSK Asthma & COPD Products Offered
  • 11.1.5 GSK Recent Development
• 11.2 Novartis
  • 11.2.1 Novartis Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Novartis Asthma & COPD Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Novartis Asthma & COPD Products Offered
  • 11.2.5 Novartis Recent Development
• 11.3 Merck
  • 11.3.1 Merck Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Merck Asthma & COPD Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Merck Asthma & COPD Products Offered
  • 11.3.5 Merck Recent Development
• 11.4 Abbott
  • 11.4.1 Abbott Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Abbott Asthma & COPD Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Abbott Asthma & COPD Products Offered
  • 11.4.5 Abbott Recent Development
• 11.5 Boehringer Ingelheim
  • 11.5.1 Boehringer Ingelheim Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Boehringer Ingelheim Asthma & COPD Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Boehringer Ingelheim Asthma & COPD Products Offered
  • 11.5.5 Boehringer Ingelheim Recent Development
• 11.6 AstraZeneca
  • 11.6.1 AstraZeneca Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 AstraZeneca Asthma & COPD Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 AstraZeneca Asthma & COPD Products Offered
  • 11.6.5 AstraZeneca Recent Development
• 11.7 Roche
  • 11.7.1 Roche Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Roche Asthma & COPD Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Roche Asthma & COPD Products Offered
  • 11.7.5 Roche Recent Development
• 11.8 Teva
  • 11.8.1 Teva Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Teva Asthma & COPD Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Teva Asthma & COPD Products Offered
  • 11.8.5 Teva Recent Development
• 11.9 Vectura
  • 11.9.1 Vectura Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Vectura Asthma & COPD Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Vectura Asthma & COPD Products Offered
  • 11.9.5 Vectura Recent Development
• 11.10 Pfizer
  • 11.10.1 Pfizer Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Pfizer Asthma & COPD Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Pfizer Asthma & COPD Products Offered
  • 11.10.5 Pfizer Recent Development
• 11.11 Mylan
• 11.12 Allergan
• 11.13 Cipla
• 11.14 Akorn

12 Future Forecast

• 12.1 Asthma & COPD Market Forecast by Regions
  • 12.1.1 Global Asthma & COPD Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Asthma & COPD Revenue Forecast by Regions 2019-2025
• 12.2 Asthma & COPD Market Forecast by Product
  • 12.2.1 Global Asthma & COPD Sales Forecast by Product 2019-2025
  • 12.2.2 Global Asthma & COPD Revenue Forecast by Product 2019-2025
• 12.3 Asthma & COPD Market Forecast by End User
• 12.4 North America Asthma & COPD Forecast
• 12.5 Europe Asthma & COPD Forecast
• 12.6 Asia Pacific Asthma & COPD Forecast
• 12.7 Central & South America Asthma & COPD Forecast
• 12.8 Middle East and Africa Asthma & COPD Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Asthma & COPD Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

Chronic obstructive pulmonary disease (COPD) is a general term that describes progressive respiratory diseases like emphysema and chronic bronchitis. COPD is characterized by decreased airflow over time, as well as inflammation of the tissues that line the airway.
Asthma is usually considered a separate respiratory disease, but sometimes it’s mistaken for COPD. The two have similar symptoms. These symptoms include chronic coughing, wheezing, and shortness of breath.
Currently, North America leads the global market for asthma & COPD drugs and devices. North America was followed by Europe in terms of market capitalization. However, North America and Europe is expected to lose out some of the market share to other emerging regional markets owing to the expiry of several patens of pharmaceutical companies operating in these regions. Asia Pacific is expected to be the fastest regional market for asthma and COPD owing to the increased incidence of asthma & other respiratory diseases in industrial regions.
The global Asthma & COPD market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Asthma & COPD market based on company, product type, end user and key regions.

This report studies the global market size of Asthma & COPD in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Asthma & COPD in these regions.
This research report categorizes the global Asthma & COPD market by top players/brands, region, type and end user. This report also studies the global Asthma & COPD market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
GSK
Novartis
Merck
Abbott
Boehringer Ingelheim
AstraZeneca
Roche
Teva
Vectura
Pfizer
Mylan
Allergan
Cipla
Akorn

Market size by Product
Anti-inflammatory Drugs
Bronchodilator Monotherapy
Combination Drugs
Market size by End User
Hospital Pharmacies
Private Clinics
Drug Stores
Retail Pharmacies
E-Commerce

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Asthma & COPD market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Asthma & COPD market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Asthma & COPD companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Asthma & COPD submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Asthma & COPD are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Asthma & COPD market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.